Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Gränges in merger control matters in connection with the acquisition of Impexmetal (Aluminium Konin)
Mandate

Vinge has advised Gränges in merger control matters in connection with the acquisition of Impexmetal (Aluminium Konin)

December 08, 2020 EU, Competition and Regulatory

Vinge has advised Gränges AB (publ) in merger control matters in connection with the acquisition of Impexmetal (Aluminium Konin).

The concentration was notified to, inter alia, the European Commission. After a thorough pre-nonfiction phase and formal review, which included several market contacts, the concentration, which results in a combination of the parties’ production of flat rolled aluminium products in the EU, was unconditionally approved by the European Commission after a phase 1 review on the 23 September 2020.

The decision is available at:  https://ec.europa.eu/competition/mergers/cases1/202050/m9560_488_3.pdf

Vinge’s team consisted mainly of Pär Remnelid, Johan Wahlbom and Julia Söderdahl.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025